Ratification of Africa Medicines Agency Treaty Inches Forward – Africa CDC Head Calls It ‘Much-Needed’ 16/10/2020 Paul Adepoju IBADAN, Nigeria – Nearly two years after the Assembly of the African Union, adopted a milestone treaty establishing an African Medicines Agency (AMA) that could provide a more unified approach to regulatory approval of new medicines and vaccines, the AMA treaty is yet to enter into force – because it has not been ratified by […] Continue reading -> The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen 't Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> China, Republic of Korea Join COVAX Global Vaccine Pool – WHO Urges Countries To Jumpstart Vaccine Campaigns 09/10/2020 Elaine Ruth Fletcher & Madeleine Hoecklin China has announced that it will join the WHO co-sponsored COVAX vaccine procurement pool, along with the Republic of Korea. WHO’s Director General Dr Tedros described it as a major boost to the global effort to manufacture and distribute 2 billion vaccines worldwide equitably by the end of 2021. “This week, China and the Republic […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> Progress On COVID-19 Technology Pool Inches Along As Sister Initiative To Pool Vaccine Procurement Accelerates 25/09/2020 Grace Ren While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading -> 64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The Indian/South African Proposal For a WTO Waiver On IP For COVID-19 Related Health Products – What It Means? 14/10/2020 Ellen 't Hoen A sweeping proposal by India and South Africa to suspend the protection of intellectual property (IP) related to COVID-19 health products is set to come before the The World Trade Organization’s TRIPS Council this week. The closed door discussion lays the groundwork for what could prove to be the most significant public debate over […] Continue reading -> China, Republic of Korea Join COVAX Global Vaccine Pool – WHO Urges Countries To Jumpstart Vaccine Campaigns 09/10/2020 Elaine Ruth Fletcher & Madeleine Hoecklin China has announced that it will join the WHO co-sponsored COVAX vaccine procurement pool, along with the Republic of Korea. WHO’s Director General Dr Tedros described it as a major boost to the global effort to manufacture and distribute 2 billion vaccines worldwide equitably by the end of 2021. “This week, China and the Republic […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> Progress On COVID-19 Technology Pool Inches Along As Sister Initiative To Pool Vaccine Procurement Accelerates 25/09/2020 Grace Ren While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading -> 64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
China, Republic of Korea Join COVAX Global Vaccine Pool – WHO Urges Countries To Jumpstart Vaccine Campaigns 09/10/2020 Elaine Ruth Fletcher & Madeleine Hoecklin China has announced that it will join the WHO co-sponsored COVAX vaccine procurement pool, along with the Republic of Korea. WHO’s Director General Dr Tedros described it as a major boost to the global effort to manufacture and distribute 2 billion vaccines worldwide equitably by the end of 2021. “This week, China and the Republic […] Continue reading -> Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> Progress On COVID-19 Technology Pool Inches Along As Sister Initiative To Pool Vaccine Procurement Accelerates 25/09/2020 Grace Ren While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading -> 64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Moderna Makes Milestone Pledge To “Not Enforce Our Patents” On COVID-19 Vaccine Technologies During Pandemic & Issue Open Licenses Afterward 08/10/2020 Raisa Santos & Elaine Ruth Fletcher Moderna, Inc., developer of one of the four front-running COVID-19 vaccine candidates, announced on Thursday that the the company would “not enforce” its COVID-19-related patents against other companies making vaccines to combat the pandemic – and would also be willing to license intellectual property for their COVID-19 vaccines for the post pandemic period. “We feel […] Continue reading -> Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> Progress On COVID-19 Technology Pool Inches Along As Sister Initiative To Pool Vaccine Procurement Accelerates 25/09/2020 Grace Ren While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading -> 64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Moderna’s COVID-19 Vaccine Unlikely To Be Available To Public Before Spring, 2021; Initial US FDA Authorization Would Be Sought In Late November 01/10/2020 Madeleine Hoecklin Moderna intends to seek US Food and Drug Administration emergency authorization for its COVID-19 vaccine candidate for frontline medical workers by November 25th at the earliest, and only in late January for use in the general population. That means that the vaccine, if approved on schedule, would only be available for widespread distribution to the […] Continue reading -> Progress On COVID-19 Technology Pool Inches Along As Sister Initiative To Pool Vaccine Procurement Accelerates 25/09/2020 Grace Ren While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading -> 64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Progress On COVID-19 Technology Pool Inches Along As Sister Initiative To Pool Vaccine Procurement Accelerates 25/09/2020 Grace Ren While the COVAX Facility, a global initiative to pool procurement of a safe and effective COVID-19 vaccine, has been gaining momentum, another global initiative to pool intellectual property rights for tools to combat the pandemic has been moving at a much slower pace. Only three more countries have signed on to support the COVID-19 Technology […] Continue reading -> 64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
64 High-Income Countries Make Binding Commitments To Buy COVID-19 Vaccines From New Global Facility – Billions Of Dollars Needed For Low-Income Nations 21/09/2020 Grace Ren Some 64 higher income countries have now made binding financial commitments to a precedent-setting COVID-19 global vaccine pool that aims to equitably distribute future vaccines to halt the pandemic raging now. Another 38 countries are expected to commit over the next week, said CEO Berkley, in a WHO press conference Monday that disclosed the landmark […] Continue reading -> Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Gilead Says Remdesivir Shortages Due To Supply Chain Issues, Civil Society Argues For Wider Licensing 03/09/2020 Svĕt Lustig Vijay As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls. Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading -> US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
US Biomedical Advanced Research & Development Agency Reviews Moderna’s US Patents For Alleged Failure To Disclose Federal Funding 03/09/2020 Grace Ren The US Biomedical Advanced Research and Development Agency (BARDA) is investigating Moderna’s patents for allegedly failing to disclose federal funding, making it the second US agency to review the company’s patents. The BARDA probe comes just days after the US Defense Advanced Research Projects Agency (DARPA) began an investigation into Moderna’s patents, after pharma watchdog […] Continue reading -> EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
EU Orphan Drug Regulations Haven’t “Failed” But Reforms Needed, Says CEO Of European Rare Disease NGO 04/08/2020 Svĕt Lustig Vijay European legislation on drugs for rare diseases is “far from perfect”, but it is not a ‘failure’ given the amount of private sector investment it has attracted in the past two decades, says Yann Le Cam, CEO of EURORDIS – Rare Diseases Europe, a non-profit alliance of some 930 rare disease patient organisations across 72 […] Continue reading -> Posts navigation Older postsNewer posts